Evaluation of apoptotic and anti-metastatic effects by modified mesoporous silica nanoparticles (MSNs) with Zn and NH2 containing cisplatin on HT-29 cell line
Source abstract
Abstract
Colorectal cancer ranks third in terms of diagnosis and second concerning cancer-related mortality. The current research is aimed to synthesize cisplatin-loaded mesoporous silica nanoparticles modified with NH2 and zinc (Zn-MSN-NH2-CP) through a sol–gel process and test their cytotoxicity against colon cancer cells in vitro. HT-29 and HUVEC cell lines were grown in supplemented DMEM medium. MTT test was used to determine the cytotoxicity of prepared formulations against normal cells as well as cancer cells. Real-time PCR was utilized to assess the expression of the apoptotic genes in HT-29 treated with CP, Zn-MSN-NH2, and Zn-MSN-NH2-CP. Necrosis or early and late apoptosis were also evaluated in cancerous cells through the flow method. Physicochemical characteristics of Zn-MSN-NH2 were assessed by SEM, TEM, DLS, and FT-IR techniques. According to the release profile, surface modification of Zn-MSN-NH2-CP resulted in a more regulated CP release. The Zn-MSN-NH2-CP was more stable at 4 °C. Cancerous cells were significantly affected by the cytotoxic effects of both CP and Zn-MSN-NH2-CP. Zn-MSN-NH2 could also minimize the toxicity of the unbound drug towards normal cells, while considerably increasing its viability. Compared to the controls, the expression of pro-apoptotic genes was enhanced in cells treated with IC50 concentrations of Zn-MSN-NH2-CP and CP, while the expression of BCL-2 mRNA showed a decline. Flow cytometry findings also revealed a substantial increase in the early and late apoptosis in cells treated with Zn-MSN-NH2-CP. These in-vitro findings introduce Zn-MSN-NH2 as a promising nanocarrier for increasing the bioavailability and anti-cancer efficacy of CP in colon cancer cells. Graphical Abstract
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Chemotherapy-induced organ toxicity mitigation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Douaiher J et al (2017) Colorectal cancer—global burden, trends, and geographical variations. J Surg Oncol 115(5):619–630. https://doi.org/10.1002/jso.2457810.1002/jso.24578 ↗
2. Siegel RL et al (2020) Colorectal cancer statistics,2020. CA: Cancer J Clin 70(3):145–164. https://doi.org/10.3322/caac.2160110.3322/caac.21601 ↗
3. Sawicki T et al (2021) A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers 13(9):2025. https://doi.org/10.3390/cancers1309202510.3390/cancers13092025 ↗
4. Sargent D et al (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27(6):872. https://doi.org/10.1200/JCO.2008.19.536210.1200/JCO.2008.19.5362 ↗
5. Shah MA et al (2016) Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database. J Clin Oncol 34(8):843. https://doi.org/10.1200/JCO.2015.63.055810.1200/JCO.2015.63.0558 ↗
6. Lee CS, Ryan EJ, Doherty GA (2014) Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol: WJG 20(14):3751. https://doi.org/10.3748/wjg.v20.i14.375110.3748/wjg.v20.i14.3751 ↗
7. Jurj A et al (2017) The new era of nanotechnology, an alternative to change cancer treatment. Drug Des Dev Ther 11:2871. https://doi.org/10.2147/DDDT.S14233710.2147/DDDT.S142337 ↗
8. Tang F, Li L, Chen D (2012) Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 24(12):1504–1534. https://doi.org/10.1002/adma.20110476310.1002/adma.201104763 ↗
9. Vivero-Escoto JL et al (2010) Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 6(18):1952–1967. https://doi.org/10.1002/smll.20090178910.1002/smll.200901789 ↗
10. Rajani C et al (2020) Cancer-targeted chemotherapy: emerging role of the folate anchored dendrimer as drug delivery nanocarrier. Pharmaceutical applications of dendrimers. Elsevier, London, pp 151–198. https://doi.org/10.3390/molecules2517398210.3390/molecules25173982 ↗
11. Tamanoi F (2018) Mesoporous slica-based nanomaterials and biomedical applications-part A. Academic Press
12. Ali I et al (2013) Platinum compounds: a hope for future cancer chemotherapy. Anticancer Agents Med Chem 13(2):296–306. https://doi.org/10.2174/187152061131302001610.2174/1871520611313020016 ↗
13. Sastry J, Kellie SJ (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22(5):441–445. https://doi.org/10.1080/0888001059096438110.1080/08880010590964381 ↗
14. Duan X et al (2016) Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdisc Rev: Nanomed Nanobiotechnol 8(5):776–791. https://doi.org/10.1002/wnan.139010.1002/wnan.1390 ↗
15. Vivero-Escoto JL, Elnagheeb M (2015) Mesoporous silica nanoparticles loaded with cisplatin and phthalocyanine for combination chemotherapy and photodynamic therapy in vitro. Nanomaterials 5(4):2302–2316. https://doi.org/10.3390/nano504230210.3390/nano5042302 ↗
16. Varache M et al (2019) Loading of cisplatin into mesoporous silica nanoparticles: Effect of surface functionalization. Langmuir 35(27):8984–8995. https://doi.org/10.1021/acs.langmuir.9b0095410.1021/acs.langmuir.9b00954 ↗
17. Vallet-Regí M et al (2017) Mesoporous silica nanoparticles for drug delivery: Current insights. Molecules 23(1):47. https://doi.org/10.3390/molecules2301004710.3390/molecules23010047 ↗
18. Moodley T, Singh M (2019) Polymeric mesoporous silica nanoparticles for enhanced delivery of 5-fluorouracil in vitro. Pharmaceutics 11(6):288. https://doi.org/10.3390/pharmaceutics1106028810.3390/pharmaceutics11060288 ↗
19. Alipoor FJ, Asadi MH, Torkzadeh-Mahani M (2018) MIAT lncRNA is overexpressed in breast cancer and its inhibition triggers senescence and G1 arrest in MCF7 cell line. J Cell Biochem 119(8):6470–6481. https://doi.org/10.1002/jcb.2667810.1002/jcb.26678 ↗
20. Vickers NJ (2017) Animal communication: when I’m calling you, will you answer too? Curr Biol 27(14):R713–R715. https://doi.org/10.1016/j.cub.2017.05.06410.1016/j.cub.2017.05.064 ↗
21. Martínez-Carmona M, Colilla M, Vallet-Regí M (2015) Smart mesoporous nanomaterials for antitumor therapy. Nanomaterials 5(4):1906–1937. https://doi.org/10.3390/nano504190610.3390/nano5041906 ↗
22. Castillo RR, Colilla M, Vallet-Regí M (2017) Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer. Expert Opin Drug Deliv 14(2):229–243. https://doi.org/10.1080/17425247.2016.121163710.1080/17425247.2016.1211637 ↗
23. Vallet-Regí M, Colilla M, González B (2011) Medical applications of organic–inorganic hybrid materials within the field of silica-based bioceramics. Chem Soc Rev 40(2):596–607. https://doi.org/10.1039/C0CS00025F10.1039/C0CS00025F ↗
24. Lu J et al (2010) Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 6(16):1794–1805. https://doi.org/10.1002/smll.20100053810.1002/smll.201000538 ↗
25. Tao Z et al (2008) Mesoporous silica nanoparticles inhibit cellular respiration. Nano Lett 8(5):1517–1526. https://doi.org/10.1021/nl080250u10.1021/nl080250u ↗
26. Raval N et al (2019) Importance of physicochemical characterization of nanoparticles in pharmaceutical product development. Basic fundamentals of drug delivery. Elsevier, pp 369–400. https://doi.org/10.1016/B978-0-12-817909-3.00010-810.1016/B978-0-12-817909-3.00010-8 ↗
27. Liu W et al (2018) Galactosylated chitosan-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. Royal Soc Open Sci 5(12):181027. https://doi.org/10.1098/rsos.18102710.1098/rsos.181027 ↗
28. Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378. https://doi.org/10.1016/j.ejphar.2014.07.02510.1016/j.ejphar.2014.07.025 ↗
29. Gao Y et al (2011) Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles. ACS Nano 5(12):9788–9798. https://doi.org/10.1021/nn203310510.1021/nn2033105 ↗
30. Lu J et al (2007) Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3(8):1341–134610.1002/smll.200700005 ↗
31. Khosravian P et al (2016) Mesoporous silica nanoparticles functionalized with folic acid/methionine for active targeted delivery of docetaxel. Onco Targets Ther 9:7315. https://doi.org/10.2147/OTT.S11381510.2147/OTT.S113815 ↗
32. Campbell KJ, Tait SW (2018) Targeting BCL-2 regulated apoptosis in cancer. Open Biol 8(5):180002. https://doi.org/10.1098/rsob.18000210.1098/rsob.180002 ↗
33. Brentnall M et al (2013) Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol 14(1):1–9. https://doi.org/10.1186/1471-2121-14-3210.1186/1471-2121-14-32 ↗
34. Uhlmann S et al (2012) Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol 8(1):570. https://doi.org/10.1038/msb.2011.10010.1038/msb.2011.100 ↗
35. Decock J et al (2011) Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med 15(6):1254–1265. https://doi.org/10.1111/j.1582-4934.2011.01302.x10.1111/j.1582-4934.2011.01302.x ↗
36. Sharifi S, Dalir Abdolahinia E, Ghavimi MA, Dizaj SM, Aschner M, Saso L, Khan H (2022) Effect of Curcumin-Loaded Mesoporous Silica Nanoparticles on the Head and Neck Cancer Cell Line, HN5. Curr Issues Mol Biol 44(11):5247-5259. https://doi.org/10.3390/cimb4411035710.3390/cimb44110357 ↗
37. Krętowski R et al (2017) The effects of silica nanoparticles on apoptosis and autophagy of glioblastoma cell lines. Nanomaterials 7(8):230. https://doi.org/10.3390/nano708023010.3390/nano7080230 ↗
38. Sancho-Martínez SM et al (2011) Necrotic concentrations of cisplatin activate the apoptotic machinery but inhibit effector caspases and interfere with the execution of apoptosis. Toxicol Sci 122(1):73–85. https://doi.org/10.1093/toxsci/kfr09810.1093/toxsci/kfr098 ↗
39. Zhou Y et al (2018) Mesoporous silica nanoparticles for drug and gene delivery. Acta pharmaceutica sinica B 8(2):165–177. https://doi.org/10.1016/j.apsb.2018.01.00710.1016/j.apsb.2018.01.007 ↗
40. Mishra S et al (2020) Folic acid-conjugated magnetic mesoporous silica nanoparticles loaded with quercetin: a theranostic approach for cancer management. RSC Adv 10(39):23148–23164. https://doi.org/10.1039/D0RA00664E10.1039/D0RA00664E ↗